MDACC Study No:2012-0089 ( NCT No: NCT01718899)
Title:A Phase 1/2a Dose Escalation Study of PVX-410, a Multi-Peptide Cancer Vaccine, in Patients with Smoldering Multiple Myeloma
Principal Investigator:Michael Wang
Treatment Agent:PVX-410
Study Status:Closed
Study Description:The goal of this clinical research study is to test the safety of PVX-410.
This includes trying to find out the side effects of PVX-410 as well as trying
to find out how much of the vaccine can be given safely to patients. In
addition, the study will test your body’s immune response to the study vaccine
and whether PVX-410 works against SMM.

PVX-410 contains proteins that are usually found in myeloma cells. These
proteins may trigger a response from the immune system.

Montanide is an additive. When it is mixed with a vaccine like PVX-410, it may
help it to work better.

Hiltonol (also called Poly-ICLC) works by stimulating the immune system.
Because hiltonol stimulates the immune system, it may make PVX-410 work better.
Hide details for General InformationGeneral Information

Disease Group:Myeloma
Phase of Study:Phase I/Phase II
Treatment Agents:PVX-410
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:ONCoPep, Inc.
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Michael Wang
For Clinical Trial Enrollment:713-792-2860
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults